Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 17, 2022
March 02 2022 - 7:00AM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the
Company”), a leader in the discovery, development and delivery of
novel short interfering ribonucleic acid (siRNA) therapeutics for
the treatment of diseases with significant unmet medical need,
today announced that the Company will release its financial and
business results for the fourth quarter and full year ended
December 31, 2021 on Thursday, March 17, 2022.
Management will host a conference call at 8:00 a.m. EDT / 12:00
p.m. GMT on Thursday, March 17, to discuss the Company’s financial
results and provide a general business update. The conference call
will be webcast live and available on the Investors section of the
Silence website at www.silence-therapeutics.com. The webcast will
also be archived on the Company’s website.
Details of the webcast and conference call:
Dial-in details: New York, United States: +1 646 741 3167
United States: 1 877 870 9135 London, United Kingdom: +44 2071
928338 United Kingdom: 08002796619
Passcode: 3055614
Webcast link:
https://edge.media-server.com/mmc/p/k2gmhpy6
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address rare
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220302005040/en/
Silence Therapeutics plc Gem Hopkins, Head of IR and
Corporate Communications Tel: +1 (646) 637-3208
ir@silence-therapeutics.com
US Media Relations MKC Strategies Mary Conway Tel:
+1 (516) 606-6545 mconway@mkcstrategies.com
European Media Relations Consilium Strategic
Communications Mary-Jane Elliott/ Angela Gray
silencetherapeutics@consilium-comms.com Tel: +44 (0) 20 3709
5700
Spectralink (NASDAQ:SLNK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Spectralink (NASDAQ:SLNK)
Historical Stock Chart
From Jul 2023 to Jul 2024